 we report on our fourth quarter and full year 2019 financial results and provide an update on our immuno-inflammatory pipeline. 
 we ended the year with $75 million in cash and investments and anticipate that our current capital will provide a cash runway into the third quarter of 2021 without giving effect to any potential business development transactions or financing activities.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 